Jürgen Kuball

Posttransplant cells for the win? DLI and adoptive cell therapy to eradicate MRD Abstract. Relapse remains the leading cause of failure after allogeneic stem cell transplantation (allo-SCT) for hematologic malignancies. Donor lymphocyte

It was a great pleasure sharing our thoughts on how to create more impact with DLIs …. It starts with registering what we do .. ashpublications.org/hematology/a... #ASH26 @ash.hematology.org

New Dual-Target T Cell Design Boosts Attack on Solid Tumours Researchers have developed a new strategy that allows engineered T cells to recognize and respond to a single tumour antigen through two coordinated mechanisms.

And check also out www.emjreviews.com/oncology/new...

Happy Killers in Hostile Tumors: Engineering T Cells with a Built-In Survival Toolkit

And check out communities.springernature.com/posts/happy-...

Cis- and trans-binding chimeric costimulatory receptors enhance T-cell fitness and tumor control - Cellular & Molecular Immunology Cellular & Molecular Immunology - Cis- and trans-binding chimeric costimulatory receptors enhance T-cell fitness and tumor control

Giving yourself a boost to keep going is also important for T cells fighting tumors.

The trick is to make them happy 😃 through costimulation that works not only in trans but also cis. #happyT-cell

www.nature.com/articles/s41...

Two main reasons: (1) Extracting γδTCRs and engineering them into other cell types creates versatile tools to target diverse cancers; (2) γδT cells have distinct homing and functional properties that can complement the arsenal of conventional αβ T cells.

Disrupting the balance between activating and inhibitory receptors of γδT cells for effective cancer immunotherapy Nature Reviews Cancer - In this Review, Beringer and colleagues highlight how future strategies for developing immunotherapies using γδT cells and their receptors will depend on creating...

www.nature.com/articles/s41...

@jkuball.bsky.social @sotnom.bsky.social @lydialynch.bsky.social @labminguet.bsky.social

Disrupting the balance between activating and inhibitory receptors of γδT cells for effective cancer immunotherapy Nature Reviews Cancer - In this Review, Beringer and colleagues highlight how future strategies for developing immunotherapies using γδT cells and their receptors will depend on creating...

🧬 Proud to share our latest review in Nature Cancer Reviews! Our article, "Disrupting the balance between activating and inhibitory receptors of γδT cells for effective cancer immunotherapy", highlights a powerful but often overlooked player in the immunotherapy landscape.

rdcu.be/eo4RX

Major achievement of the GoCART Coalition and all authors to release the 2025 edition of the EU CAR-T handbook at #EBMT25. Thx to my co-editors, all authors, EBMT and EHA to support this amazing project that will allow to develop the CART passport! Enjoy reading 😀. www.ebmt.org/education/ca...

The use of MSCs in steroid-refractory acute GvHD in Europe: a survey from the EBMT cellular therapy & immunobiology working party Bone Marrow Transplantation - The use of MSCs in steroid-refractory acute GvHD in Europe: a survey from the EBMT cellular therapy & immunobiology working party

Still hot and happening: academic MSC for GVHD, a study of the CTIWP of The EBMT
rdcu.be/eaCcY

The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT Immune monitoring of cell therapies is a complex and evolving topic, particularly in the rapid expanding field of chimeric antigen receptor T (CAR-T) …

🚀 Fresh off the pre-proof! 🚀
Excited to share our latest work, now available in Blood Reviews
✅ Immune monitoring is widely implemented but still lacks standardization.
✅ There is an urgent need for harmonized protocols to optimize patient outcomes.

www.sciencedirect.com/science/arti...

Christian Chabannon presenting on the progress of #GoCARTcoalition a European initiative aiming to increase access to this exciting new therapies to cancer patients and patients with auto immune diseases. #EBMT #EHA #CART25

What a great pre meeting before #CART25 in Strassbourg of #T2Evolve and #GoCART coalition on developing consensus on collected CART data as well as registry interactions using OMOPing

We are proud to inform you that the survey about the CAR-T process has resulted in a stunning 227 response. Curious about first data: please join the session at QM Day April 1 at the EBMT congress in Florence, Italy!

#EBMT #JACIE #CART #GOCARTcoalition #HEMATOLOGY

lnkd.in/gQ8dQaps

Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder — recommendations from ECTRIMS and the EBMT - Nature Reviews Neurolog... Autologous haematopoietic stem cell transplantation (AHSCT) is a treatment option for some forms of multiple sclerosis (MS), but uncertainties remain about its implementation in clinical practice and ...

www.nature.com/articles/s41.... Important consensus paper for centers using autologous stem cell transplant as treatment for Multiple Sclerosis

Congrats to the winners!!! Studies with real world data on CART are so important to improve clinical practice. Looking forward to the outcome of these studies thegocartcoalition.com

Proud of Anke Janssen who finalized her PhD on the biology of gdT cells and their receptors for cancer in immunotherapies. Yuca also to the co-promotors Dennis Beringer and Moniek de Witte

research.umcutrecht.nl/news/%CE%B3%...

Excellent presentation of ⁦‪@CChabannon‬⁩ on tisagenlecleucel for the Management of Patients with R/R DLBCL: an Interim Report of the European PASS Conducted
by EBMT ⁦at #ASH24

Thx for picking up our work on MSC for GVHD at #ASH24 …. Still an interesting option

#ASH24 Fantastic E. Donnall Thomas Lecture given by Sean Morrison on Hematopoietc Stem Cell Maintenance!

Dr. Ing Soo Tiong from @petermaccc.bsky.social presenting his excellent work at #ASH24 on how the remission clonal haematopoietic landscape is shaped by venetoclax in pts with AML. TP53 and BAX microclones! With a bit more sensitive sequencing tech we will find the nanoclones… #hemepath #hemesky

Starting #ASH24 on Bluesky 😎